BUNGE LTD (BG)       96.36  +0.85 (+0.89%)

96.36  +0.85 (+0.89%)

BMG169621056 - Common Stock - After market: 96.3 -0.06 (-0.06%)


Fundamental Rating

5

Taking everything into account, BG scores 5 out of 10 in our fundamental rating. BG was compared to 102 industry peers in the Food Products industry. Both the profitability and the financial health of BG get a neutral evaluation. Nothing too spectacular is happening here. BG is valued quite cheap, while showing a decent growth score. This is a good combination!




Profitability

Profitability Rating

5

BG has a Return On Assets of 6.07%. This is better than the industry average of 1.35%.
BG has a Return On Equity of 17.29%. This is better than the industry average of 13.46%.

BG's Profit Margin of 2.24% is in line with the rest of the industry. The industry average Profit Margin is 2.24%.
BG has a Piotroski-F score of 4.00. This indicates an average health and profitability for BG.
VS Industry

ROA (6.07%) VS Industry: 74% outperformed.

-113.79
16.59

ROE (17.29%) VS Industry: 67% outperformed.

0.23
79.02

Profit Margin (2.24%) VS Industry: 50% outperformed.

-1,865.78
41.73

Valuation

Valuation Rating

7

With a Price/Earnings Ratio of 6.80, the valuation of BG can be described as very cheap.
Compared to an average industry Price/Earning Ratio of 20.10, BG is valued rather cheaply. On top of this BG is cheaper than 90% of the companies listed in the same industry.
The Forward Price/Earnings Ratio of 7.93 indicates a rather cheap valuation of BG.
Compared to an average Enterprise Value to EBITDA ratio of 13.95, BG is valued rather cheaply. On top of this, BG has a better ratio than 85% of the companies listed in the same industry.

When comparing the current price to the book value of BG, we can conclude it is valued correctly. It is trading at 1.66 times its book value.
When comparing the price book ratio of BG to the average industry price book ratio of 1.74, BG is valued in line with its industry peers.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates BG does not grow enough to justify the current Price/Earnings ratio.
VS Industry

Price/Earnings (6.8) VS Industry: 90% outperformed.

660.50
0.31

Price/Book (1.66) VS Industry: 52% outperformed.

30.56
0.02

Enterprise Value/ EBITDA (5.39) VS Industry: 85% outperformed.

450.02
0.27

Growth

Growth Rating

4

BG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.27%, which is quite good.
Measured over the past 5 years, BG shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.84% on average per year.
BG shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.11%.
The Earnings Per Share is expected to decrease by -8.53% on average over the next 5 years.

The Revenue has been growing slightly by 6.75% on average over the past 5 years.
Based on estimates for the next 5 years, BG will show a small growth in Revenue. The Revenue will grow by 1.95% on average per year.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS22.84% 69.91% 13.27% 1.37% -3.15% -6.51% -8.53%
Revenue6.75% 8.95% 22.11% 21.24% 8.84% 5.46% 1.95%

Health

Health Rating

6

An Altman-Z score of 4.46 indicates that BG is not in any danger for bankruptcy at the moment.
The Altman-Z score of BG is much better than the industry average of 2.23. BG has a better rating than 85% of its industry peers.
A Current Ratio of 1.63 indicates that BG should not have too much problems paying its short term obligations.
The Current Ratio is in line with the industry averages, which is at 1.81.

The Quick Ratio is in line with the industry averages, which is at 0.88.
The Debt to Equity ratio of BG is in line with the industry averages.
The Piotroski-F score of BG is 4.00. This is a neutral score and indicates average health and profitability for BG.
BG has a Quick Ratio of 1.63. This is a bad value and indicates that BG is not financially healthy enough and could expect problems in meeting its short term obligations.
VS Industry

Debt/Equity (0.34) VS Industry: 57% outperformed.

5.29
0.00

Quick Ratio (0.86) VS Industry: 49% outperformed.

0.10
37.12

Current Ratio (1.63) VS Industry: 44% outperformed.

0.13
37.46

Altman-Z (4.46) VS Industry: 85% outperformed.

-21.57
16.98

Dividend

Dividend Rating

5

22.52% of the earnings are spent on dividend by BG. This is a low number and sustainable payout ratio.
BG has been paying a dividend for at least 10 years, so it has a reliable track record.
BG has a Yearly Dividend Yield of 2.46%. Purely for dividend investing, there may be better candidates out there.
Compared to an average S&P500 Dividend Yield of 2.43, BG has a dividend comparable with the average S&P500 company.

The dividend of BG has a limited annual growth rate of 2.21%.
Compared to an average industry Dividend Yield of 2.96, BG is paying slightly less dividend.
BG's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
VS Industry

Dividend Yield (2.46%) VS Industry: 33% outperformed.

0.79
19.70
BG Daily chart

BUNGE LTD96.36

NYSE:BG (12/8/2022, 4:05:00 PM)+0.85 (+0.89%)

After market: 96.3 -0.06 (-0.06%)

Chartmill FA Rating
GICS Sector Consumer Staples
GICS IndustryGroup Food, Beverage & Tobacco
GICS Industry Food Products
Earnings (Last) 10-26 2022-10-26/bmo Earnings (Next) 02-07 2023-02-07
Ins Owners 1.2% Inst Owners 83.82%
Market Cap 14.43B Analysts 86
Valuation
PE 6.8 Fwd PE 7.93
PEG (NY) 4.98 PEG (5Y) 0.3
P/S 0.21 P/B 1.66
EV/EBITDA 5.39
Dividend
Dividend Yield 2.46% Dividend Growth 2.21%
DP 22.52% Ex-Date 11-17 2022-11-17 (0.625)
Growth
EPS 1Y 13.27% EPS 3Y 69.91%
EPS 5Y 22.84% EPS growth Q2Q -7.26%
EPS Next Y 1.37% EPS Next 2Y -3.15%
EPS Next 3Y -6.51% EPS Next 5Y -8.53%
Revenue growth 1Y 22.11% Revenue growth 3Y 8.95%
Revenue growth 5Y 6.75% Revenue growth Q2Q 18.72%
Revenue Next Year 21.24% Revenue Next 2Y 8.84%
Revenue Next 3Y 5.46% Revenue Next 5Y 1.95%
Health
Current Ratio 1.63 Quick Ratio 0.86
Altman-Z 4.46 F-Score 4
Debt/Equity 0.34 WACC 7.05%
ROIC/WACC 2.25
Profitability
ROA 6.07% ROE 17.29%
ROICexgc 15.86% ROIC 13.37%
PM 2.24% OM 3.71%
Asset Turnover 2.71

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA